Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19918764 | 1.00 | NOS1 (0.37) | NOS1TBXAS1HSP90AA1CNR1CNR2 | |
| SCHEMBL18557133 | 1.00 | NOS1 (0.37) | NOS1TBXAS1HSP90AA1CNR1CNR2 | |
| SCHEMBL19250952 | 1.00 | NOS1 (0.37) | NOS1TBXAS1HSP90AA1CNR1CNR2 | |
| SCHEMBL22856659 | 0.97 | NOS1 (0.36) | NOS1TBXAS1HSP90AA1 | |
| SCHEMBL19738701 | 0.93 | NOS1 (0.36) | NOS1TBXAS1HSP90AA1 | |
| SCHEMBL25144417 | 0.86 | NOS1 (0.37) | NOS1TBXAS1HSP90AA1CNR1CNR2 | |
| SCHEMBL21191569 | 0.86 | NOS1 (0.37) | NOS1TBXAS1HSP90AA1CNR1CNR2 | |
| SCHEMBL22513592 | 0.85 | NOS1 (0.33) | NOS1 | |
| SCHEMBL2404365 | 0.81 | NOS1 (0.39) | NOS1TBXAS1HSP90AA1 | |
| SCHEMBL15979329 | 0.78 | NOS1 (0.32) | NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | HIF1AN, EGLN3, EGLN2 | NOS1 1031/4885TBXAS1 2192/4885HSP90AA1 197/4885 |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | NOS1 1060/4885TBXAS1 2563/4885HSP90AA1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.